ciprofloxacin has been researched along with Burns in 30 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Burns: Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This research focuses on the feasibility of using silver- and fluoride-containing BGs against multidrug-resistant bacterial strains isolated from patients with burns." | 7.83 | Silver- and fluoride-containing mesoporous bioactive glasses versus commonly used antibiotics: Activity against multidrug-resistant bacterial strains isolated from patients with burns. ( Gholipourmalekabadi, M; Hashemi, A; Mozafari, M; Rostami, A; Sameni, M; Zamani, F, 2016) |
| " The recommended dosage regimen for administration of CPF, i." | 6.69 | Clinical pharmacokinetics of ciprofloxacin in patients with major burns. ( Bourget, P; Goudin, C; Latarjet, J; Lesne-Hulin, A; Ravat, F, 1999) |
| "The purpose of this work was to develop an effective carbomer hydrogel to be used to treat second-degree burns that combined ciprofloxacin and lidocaine (CbCipLid hydrogel)." | 3.88 | Ciprofloxacin-lidocaine-based hydrogel: development, characterization, and in vivo evaluation in a second-degree burn model. ( Breda, SA; Manzo, RH; Olivera, ME; Sanchez, MF; Soria, EA; Tártara, LI, 2018) |
| " This research focuses on the feasibility of using silver- and fluoride-containing BGs against multidrug-resistant bacterial strains isolated from patients with burns." | 3.83 | Silver- and fluoride-containing mesoporous bioactive glasses versus commonly used antibiotics: Activity against multidrug-resistant bacterial strains isolated from patients with burns. ( Gholipourmalekabadi, M; Hashemi, A; Mozafari, M; Rostami, A; Sameni, M; Zamani, F, 2016) |
| "First, compromised immunity caused by delayed healing of burn wounds in patients with large-area burns and long-term administration of carbapenems may be the important factors in the initiation and progression of PDRPA infection." | 3.77 | Large-area burns with pandrug-resistant Pseudomonas aeruginosa infection and respiratory failure. ( Bian, J; Ning, FG; Zhang, GA; Zhao, XZ, 2011) |
| "Food and Drug Administration regulations state that ciprofloxacin hydrochloride may cause arthropathies." | 3.70 | Ciprofloxacin as a therapeutic modality in pediatric burn wound infections: efficacious or contraindicated? ( Desai, M; Edgar, P; Heggers, JP; Herndon, DN; John, SD; Klein, GL; Villarreal, C; Wolf, S, 1998) |
| " The recommended dosage regimen for administration of CPF, i." | 2.69 | Clinical pharmacokinetics of ciprofloxacin in patients with major burns. ( Bourget, P; Goudin, C; Latarjet, J; Lesne-Hulin, A; Ravat, F, 1999) |
| "Many drugs exhibit altered pharmacokinetic parameters in burn patients." | 2.68 | Ciprofloxacin pharmacokinetics in burn patients. ( Garrelts, JC; Jost, G; Kowalsky, SF; Krol, GJ; Lettieri, JT, 1996) |
| " Furthermore, reducing the dosage of antibiotics can lead to an improvement in the toxic effects caused by dose-dependent antibiotics and antimicrobial activity." | 1.91 | Evaluation of combined carbon dots and ciprofloxacin on the expression level of pslA, pelA, and ppyR genes and biofilm production in ciprofloxacin-resistant Pseudomonas aeruginosa isolates from burn wound infection in Iran. ( Abiri, R; Alvandi, AH; Barati, A; Delnavazi, MR; Karimiravesh, R; Mobarez, AM; Nikkhah, M; Pajavand, H, 2023) |
| "aeruginosa murine burn wound infection." | 1.42 | Efficacy of purified lactonase and ciprofloxacin in preventing systemic spread of Pseudomonas aeruginosa in murine burn wound model. ( Chhibber, S; Gupta, P; Harjai, K, 2015) |
| "To achieve this, a burn wound infection model was established in mice by using a highly pathogenic burn wound clinical isolate of P." | 1.32 | Therapeutic efficacy of "nubiotics" against burn wound infection by Pseudomonas aeruginosa. ( Dale, RM; Schnell, G; Wong, JP, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.67) | 18.7374 |
| 1990's | 7 (23.33) | 18.2507 |
| 2000's | 7 (23.33) | 29.6817 |
| 2010's | 8 (26.67) | 24.3611 |
| 2020's | 6 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takeda, S | 1 |
| Nakai, T | 1 |
| Wakai, Y | 1 |
| Ikeda, F | 1 |
| Hatano, K | 1 |
| Calum, H | 1 |
| Trøstrup, H | 1 |
| Laulund, AS | 1 |
| Thomsen, K | 1 |
| Christophersen, L | 1 |
| Høiby, N | 1 |
| Moser, C | 1 |
| Amiri, P | 1 |
| Kardan-Yamchi, J | 1 |
| Kazemian, H | 1 |
| Rezaei, F | 1 |
| Sanchez, MF | 2 |
| Guzman, ML | 1 |
| Flores-Martín, J | 1 |
| Cruz Del Puerto, M | 1 |
| Laino, C | 1 |
| Soria, EA | 2 |
| Donadio, AC | 1 |
| Genti-Raimondi, S | 1 |
| Olivera, ME | 2 |
| Pajavand, H | 1 |
| Mobarez, AM | 1 |
| Barati, A | 1 |
| Nikkhah, M | 1 |
| Delnavazi, MR | 1 |
| Abiri, R | 1 |
| Alvandi, AH | 1 |
| Karimiravesh, R | 1 |
| Raouf, M | 1 |
| Essa, S | 1 |
| El Achy, S | 1 |
| Essawy, M | 1 |
| Rafik, S | 1 |
| Baddour, M | 1 |
| Hashemzadeh, M | 1 |
| Heydari, R | 1 |
| Asareh Zadegan Dezfuli, A | 1 |
| Saki, M | 1 |
| Meghdadi, H | 1 |
| Bakhtiyariniya, P | 1 |
| Khosravi, AD | 1 |
| Motahar, M | 1 |
| Abbasi Montazeri, E | 1 |
| Breda, SA | 1 |
| Tártara, LI | 1 |
| Manzo, RH | 1 |
| Nichols, DP | 1 |
| Caceres, S | 1 |
| Caverly, L | 1 |
| Fratelli, C | 1 |
| Kim, SH | 1 |
| Malcolm, K | 1 |
| Poch, KR | 1 |
| Saavedra, M | 1 |
| Solomon, G | 1 |
| Taylor-Cousar, J | 1 |
| Moskowitz, S | 1 |
| Nick, JA | 1 |
| Gupta, P | 1 |
| Chhibber, S | 1 |
| Harjai, K | 1 |
| Gholipourmalekabadi, M | 1 |
| Sameni, M | 1 |
| Hashemi, A | 1 |
| Zamani, F | 1 |
| Rostami, A | 1 |
| Mozafari, M | 1 |
| Hsieh, TC | 1 |
| Jean, SS | 1 |
| Ou, TY | 1 |
| Chen, FL | 1 |
| Lee, WS | 1 |
| Roy, DC | 1 |
| Tomblyn, S | 1 |
| Isaac, KM | 1 |
| Kowalczewski, CJ | 1 |
| Burmeister, DM | 1 |
| Burnett, LR | 1 |
| Christy, RJ | 1 |
| Ning, FG | 1 |
| Zhao, XZ | 1 |
| Bian, J | 1 |
| Zhang, GA | 1 |
| Dale, RM | 1 |
| Schnell, G | 1 |
| Wong, JP | 1 |
| Ferreira, AC | 1 |
| Gobara, S | 1 |
| Costa, SE | 1 |
| Sauaia, N | 1 |
| Mamizuka, EM | 1 |
| van der Heijden, IM | 1 |
| Soares, RE | 1 |
| Almeida, GD | 1 |
| Fontana, C | 1 |
| Levin, AS | 1 |
| Khorasani, G | 1 |
| Salehifar, E | 1 |
| Eslami, G | 1 |
| Boyce, ST | 1 |
| Warden, GD | 1 |
| Holder, IA | 1 |
| Garrelts, JC | 1 |
| Jost, G | 1 |
| Kowalsky, SF | 1 |
| Krol, GJ | 1 |
| Lettieri, JT | 1 |
| Heggers, JP | 1 |
| Villarreal, C | 1 |
| Edgar, P | 1 |
| Wolf, S | 1 |
| Klein, GL | 1 |
| John, SD | 1 |
| Desai, M | 1 |
| Herndon, DN | 1 |
| Lesne-Hulin, A | 1 |
| Bourget, P | 1 |
| Ravat, F | 1 |
| Goudin, C | 1 |
| Latarjet, J | 1 |
| Varela, JE | 1 |
| Cohn, SM | 1 |
| Brown, M | 1 |
| Ward, CG | 1 |
| Namias, N | 1 |
| Spalding, PB | 1 |
| Krutikov, MG | 1 |
| Estahbanati, HK | 1 |
| Kashani, PP | 1 |
| Ghanaatpisheh, F | 1 |
| Zhang, YP | 1 |
| Collins, MS | 3 |
| Ladehoff, D | 1 |
| Mehton, NS | 1 |
| Wang, DW | 1 |
| Hector, RF | 2 |
| Roby, RE | 2 |
| Edwards, AA | 1 |
| Ladehoff, DK | 1 |
| Dorsey, JH | 2 |
| Tsay, GC | 1 |
2 reviews available for ciprofloxacin and Burns
| Article | Year |
|---|---|
Murine burn lesion model for studying acute and chronic wound infections.
Topics: Animals; Biofilms; Burns; Calgranulin A; Ciprofloxacin; Disease Models, Animal; Humans; Mice; Pseudo | 2022 |
[Prospects of clinical uses of quinolones in burn wound infections].
Topics: Animals; Anti-Infective Agents; Burns; Ciprofloxacin; Humans; Norfloxacin; Wound Infection | 1990 |
4 trials available for ciprofloxacin and Burns
| Article | Year |
|---|---|
Ciprofloxacin pharmacokinetics in burn patients.
Topics: Adolescent; Adult; Anti-Infective Agents; Burns; Ciprofloxacin; Dose-Response Relationship, Drug; Fe | 1996 |
Clinical pharmacokinetics of ciprofloxacin in patients with major burns.
Topics: Adult; Aged; Anti-Infective Agents; Area Under Curve; Burns; Ciprofloxacin; Female; Humans; Male; Me | 1999 |
Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Area Under Curve; Bacterial Infections; Burns | 2000 |
[A trial of the clinical use of Cifran in treating infections in burn wounds and the infectious complications of burns].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Burns; Burns, Inhalation; Ciprofloxacin; Female; Hum | 2000 |
24 other studies available for ciprofloxacin and Burns
| Article | Year |
|---|---|
In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
Topics: Animals; beta-Lactamases; Burns; Cephalosporins; Drug Resistance, Multiple, Bacterial; Lung Diseases | 2007 |
Antibacterial activity of chitosan-based nanohybrid membranes against drug-resistant bacterial isolates from burn wound infections.
Topics: Anti-Bacterial Agents; Bentonite; Burns; Chitosan; Ciprofloxacin; Humans; Methicillin-Resistant Stap | 2022 |
Ionic complexation improves wound healing in deep second-degree burns and reduces in-vitro ciprofloxacin cytotoxicity in fibroblasts.
Topics: Alginates; Anti-Bacterial Agents; Burns; Ciprofloxacin; Fibroblasts; Humans; Hydrogels; Integrin bet | 2022 |
Evaluation of combined carbon dots and ciprofloxacin on the expression level of pslA, pelA, and ppyR genes and biofilm production in ciprofloxacin-resistant Pseudomonas aeruginosa isolates from burn wound infection in Iran.
Topics: Anti-Bacterial Agents; Biofilms; Burns; Ciprofloxacin; Humans; Iran; Microbial Sensitivity Tests; Ps | 2023 |
Evaluation of Combined Ciprofloxacin and azithromycin free and nano formulations to control biofilm producing Pseudomonas aeruginosa isolated from burn wounds.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Biofilms; Burns; Ciprofloxacin; Drug Therapy, Combinat | 2021 |
Occurrence of Multiple-Drug Resistance Bacteria and Their Antimicrobial Resistance Patterns in Burn Infections from Southwest of Iran.
Topics: Anti-Bacterial Agents; Bacteria; Burns; Ciprofloxacin; Drug Resistance, Bacterial; Drug Resistance, | 2022 |
The frequency of class1 and 2 integrons in Pseudomonas aeruginosa strains isolated from burn patients in a burn center of Ahvaz, Iran.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Burn Units; Burns; Ciprofloxacin; Gentamicins; Humans; In | 2017 |
Ciprofloxacin-lidocaine-based hydrogel: development, characterization, and in vivo evaluation in a second-degree burn model.
Topics: Administration, Topical; Animals; Burns; Ciprofloxacin; Disease Models, Animal; Hydrogels; Lidocaine | 2018 |
Effects of azithromycin in Pseudomonas aeruginosa burn wound infection.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Burns; Ciprofloxacin; Disease Models, Animal; Drug Syn | 2013 |
Efficacy of purified lactonase and ciprofloxacin in preventing systemic spread of Pseudomonas aeruginosa in murine burn wound model.
Topics: Animals; Anti-Bacterial Agents; Burns; Chemokine CXCL2; Ciprofloxacin; Disease Models, Animal; Inter | 2015 |
Silver- and fluoride-containing mesoporous bioactive glasses versus commonly used antibiotics: Activity against multidrug-resistant bacterial strains isolated from patients with burns.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Aztreonam; Burns; Carbenicillin; Cefepime; Ceftazidime; Ce | 2016 |
Starch dust explosion and flame burn injury in a patient complicated with severe cellulites caused by non-O1 Vibrio cholerae.
Topics: Anti-Bacterial Agents; Burns; Cellulite; Ciprofloxacin; Dust; Explosions; Humans; Male; Microbial Se | 2016 |
Ciprofloxacin-loaded keratin hydrogels reduce infection and support healing in a porcine partial-thickness thermal burn.
Topics: Animals; Burns; Ciprofloxacin; Disease Models, Animal; Drug Carriers; Female; Hydrogels; Keratins; M | 2016 |
Large-area burns with pandrug-resistant Pseudomonas aeruginosa infection and respiratory failure.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Burns; Carbapenems; Ciprofloxacin; Drug Resistance, Multip | 2011 |
Therapeutic efficacy of "nubiotics" against burn wound infection by Pseudomonas aeruginosa.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Burns; Ciprofloxacin | 2004 |
Emergence of resistance in Pseudomonas aeruginosa and Acinetobacter species after the use of antimicrobials for burned patients.
Topics: Acinetobacter; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Burns; Ciprofloxacin; Cohort Stu | 2004 |
Profile of microorganisms and antimicrobial resistance at a tertiary care referral burn centre in Iran: emergence of Citrobacter freundii as a common microorganism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Burns; Child; Ciprofloxacin; Citr | 2008 |
Noncytotoxic combinations of topical antimicrobial agents for use with cultured skin substitutes.
Topics: Administration, Topical; Amphotericin B; Burns; Candida; Cells, Cultured; Ciprofloxacin; Culture Tec | 1995 |
Ciprofloxacin as a therapeutic modality in pediatric burn wound infections: efficacious or contraindicated?
Topics: Adolescent; Age Factors; Anti-Infective Agents; Biopsy; Burns; Child; Child, Preschool; Ciprofloxaci | 1998 |
Frequency of Pseudomonas aeruginosa serotypes in burn wound infections and their resistance to antibiotics.
Topics: Acinetobacter; Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Burns; Carbenicillin; Ceftazidi | 2002 |
[Common pathogens in burn infection and changes in their drug sensitivity].
Topics: Amikacin; Burns; Ciprofloxacin; Female; Humans; Male; Microbial Sensitivity Tests; Piperacillin; Pro | 1991 |
Therapy of established experimental Pseudomonas aeruginosa infections with oral ciprofloxacin and five human monoclonal antibodies against lipopolysaccharide antigens.
Topics: Animals; Antibodies, Monoclonal; Antigens, Bacterial; Burns; Cellulitis; Ciprofloxacin; Immunotherap | 1991 |
[Prevention of gram-negative and gram-positive infections with 3 intravenous immunoglobulin preparations and therapy of experimental polymicrobial burn infection with intravenous Pseudomonas immunoglobulin G and ciprofloxacin in an animal model].
Topics: Animals; Bacterial Infections; Burns; Ciprofloxacin; Combined Modality Therapy; Female; Immunoglobul | 1987 |
Therapy of experimental Pseudomonas burn wound sepsis with ciprofloxacin and Pseudomonas immune globulin.
Topics: ADP Ribose Transferases; Animals; Antibodies, Bacterial; Bacterial Toxins; Burns; Ciprofloxacin; Com | 1987 |